Roberto Iacovelli: My preference for ESMO Presidency is for Giuseppe Curigliano
Roberto Iacovelli shared on X/Twitter:
“The next days are so important for our Society, ESMO. New president will be elected, and two great candidates are in the runoff to make ESMO greater. My preference is for Giuseppe Curigliano. I know its value, and I am sure he will support ESMO’s growth in the coming years.”
Source: Roberto Iacovelli/X
Dr. Roberto Iacovelli, is a medical oncologist at Fondazione Policlinico Gemelli IRCCS in Rome, Italy. With a focus on genitourinary cancers, his research focuses on metastatic renal cell carcinoma, prostate, and bladder cancer, exploring predictive factors and therapy sequencing.
Dr. Iacovelli’s contributions include over 150 publications in peer-reviewed journals and numerous awards for his work, including the ASCO Cancer Foundation Merit Award in 2011.
Giuseppe Curigliano, MD, PhD, is the Director of the Early Drug Development Division and co-chairs the Experimental Therapeutics Program at the European Institute of Oncology.
He is a member of the Department of Oncology and Hemato-Oncology’s steering committee at the University of Milan and serves on the Italian National Health Council, advising the Ministry of Health on cancer policy issues.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023